Trump presses Zelenskyy to stop hitting Russian refineries

Image
US president tells Ukrainian leader in phone call it is all about ‘diesel, diesel, diesel’, according to officials 🔥 EXCLUSIVE PARTNER OFFER 2026 New T-Rex3 Pro 1100mAh Battery Smart Watch GPS path 5ATM Waterproof Sports Run tracker Outdoors Compass Military Smartwatch Special Price 🌟 Hot deal! This trending product is flying off the shelves. Get yours before it's too late! 🛒 Buy Now on AliExpress → Affiliate link — Commission earned at no extra cost to you 📰 Original source: https://www.ft.com/content/adb80fa3-b54a-4b3d-8ed2-0ebe55a5e05e?syn-25a6b1a6=1 © EcoNews DZ — Global Economic & Financial News

Haya Therapeutics Signs $1 Billion Deal with Eli Lilly




Haya Therapeutics, a Swiss biotech founded in 2019 by Algerian biologist Samir Ounzain, has signed a $1 billion deal with Eli Lilly. Based in Lausanne, the company develops RNA-based therapies to treat severe diseases by exploring the "dark genome."

The agreement focuses on identifying drug targets for obesity and associated metabolic diseases. The contract includes several milestone payments, from preclinical to commercial stages, providing a major boost to the start-up’s growth.

About Samir Ounzain:

Samir Ounzain was born in 1983 in Koléa, Algeria. After growing up in the UK, he moved to Switzerland, where he founded Haya Therapeutics after working at the Lausanne University Hospital (CHUV). He holds a degree in biochemistry and molecular biology from the University of Leeds and a PhD in molecular cardiology from the University of Leicester.




Comments

Popular posts from this blog

Xi wants China to boost demand. Why isn’t it working?

It was billed as effortless London luxury. Then tenants found out the rules

'I didn't speak the Queen's English': Why people worry about their accents